Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

NCT00060307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)